Clinical TrialsAkero announced the initiation of SYNCHRONY Outcomes, a Phase 3 trial assessing efruxifermin in MASH patients with compensated cirrhosis, fibrosis stage 4.
Drug DevelopmentEfruxifermin continues to be one of the most exciting MASH drug candidates in development from conversations and polling of physicians.
Financial HealthAkero reported Q2 2024 earnings, finishing the period with $848.3M in cash, cash equivalents, and short/long-term marketable securities, which is expected to fund operations into the second half of 2027.